{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:28:38Z","timestamp":1786613318299,"version":"build-2736575974"},"reference-count":190,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Antimicrobial resistance (AMR) remains an ongoing and critical concern with substantial consequences for global public health. Although recent attention has focused on managing Gram-negative infections, Gram-positive pathogens contribute comparably to morbidity and mortality. The increasing prevalence of multidrug-resistant (MDR) Gram-positive infections has led to the widespread use of vancomycin and other next-line agents including linezolid, daptomycin, ceftaroline and dalbavancin. However, emerging resistance to these agents is increasingly reported, further limiting the available therapeutic options for Gram-positive infections. To this end, there is an urgent need for effective strategies to overcome resistance, including combination therapy, optimization of pharmacokinetic and pharmacodynamic parameters, and improved source control to reduce infection burden. Additionally, resistance surveillance, antimicrobial stewardship and the development of novel antimicrobials are warranted to address the rising threat of resistant Gram-positive infections. This review aims to provide an overview of resistance mechanisms in major Gram-positive pathogens and discuss existing and emerging approaches to overcome resistance to agents beyond vancomycin, incorporating recent evidence on combination therapies and providing a practical treatment algorithm.<\/jats:p>","DOI":"10.3390\/antibiotics15080780","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:06:16Z","timestamp":1786608376000},"page":"780","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border"],"prefix":"10.3390","volume":"15","author":[{"given":"Despoina","family":"Papageorgiou","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Patras, Rio, 26504 Patras, Greece"},{"name":"Department of Internal Medicine, University General Hospital of Patras, Rio, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Patras, Rio, 26504 Patras, Greece"},{"name":"Department of Internal Medicine, University General Hospital of Patras, Rio, 26504 Patras, Greece"},{"name":"Division of Infectious Diseases, University General Hospital of Patras, Rio, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jubeh, B., Breijyeh, Z., and Karaman, R. (2020). Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches. Molecules, 25.","DOI":"10.3390\/molecules25122888"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rajput, P., Nahar, K.S., and Rahman, K.M. (2024). Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria. Antibiotics, 13.","DOI":"10.3390\/antibiotics13121197"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Turner, A.M., Lee, J.Y.H., Gorrie, C.L., Howden, B.P., and Carter, G.P. (2021). Genomic Insights Into Last-Line Antimicrobial Resistance in Multidrug-Resistant Staphylococcus and Vancomycin-Resistant Enterococcus. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.637656"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/20477724.2023.2285187","article-title":"Staphylococcus aureus epidemiology, pathophysiology, clinical manifestations and application of nano-therapeutics as a promising approach to combat methicillin resistant Staphylococcus aureus","volume":"118","author":"Bashabsheh","year":"2024","journal-title":"Pathog. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13059-017-1252-9","article-title":"Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice","volume":"18","author":"Harkins","year":"2017","journal-title":"Genome Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC) (2009). Classification of Staphylococcal Cassette Chromosome mec (SCC mec): Guidelines for Reporting Novel SCC mec Elements. Antimicrob. Agents Chemother., 53, 4961\u20134967.","DOI":"10.1128\/AAC.00579-09"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lade, H., and Kim, J.-S. (2023). Molecular Determinants of \u03b2-Lactam Resistance in Methicillin-Resistant Staphylococcus aureus (MRSA): An Updated Review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12091362"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Li, J., Cheng, F., Wei, X., Bai, Y., Wang, Q., Li, B., Zhou, Y., Zhai, B., Zhou, X., and Wang, W. (2025). Methicillin-Resistant Staphylococcus aureus (MRSA): Resistance, Prevalence, and Coping Strategies. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080771"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114376","DOI":"10.1016\/j.isci.2025.114376","article-title":"Methicillin-resistant Staphylococcus aureus is raising global concern as it overcomes immune challenges through various virulence mechanisms","volume":"29","author":"Thacharodi","year":"2026","journal-title":"iScience"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00020-18","DOI":"10.1128\/CMR.00020-18","article-title":"Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology","volume":"31","author":"Lakhundi","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_14","first-page":"19688","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe","volume":"15","author":"Becker","year":"2010","journal-title":"Eurosurveillance"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofaf282","DOI":"10.1093\/ofid\/ofaf282","article-title":"Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005\u20132022","volume":"12","author":"Biggs","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Morrisette, T., Alosaimy, S., Abdul-Mutakabbir, J.C., Kebriaei, R., and Rybak, M.J. (2020). The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA\u2014Salvaging the Gold Standards with Combination Therapy. Antibiotics, 9.","DOI":"10.3390\/antibiotics9110762"},{"key":"ref_17","unstructured":"(2026, March 29). Laboratory Testing for Vancomycin-Resistant Staphylococcus aureus, Available online: https:\/\/www.cdc.gov\/staphylococcus-aureus\/php\/laboratories\/index.html."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","article-title":"Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features","volume":"21","author":"Cong","year":"2020","journal-title":"J. Adv. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.1090956","article-title":"Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus","volume":"302","author":"Weigel","year":"2003","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12689","DOI":"10.1038\/s41598-020-69058-z","article-title":"Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: A systematic review and meta-analysis","volume":"10","author":"Shariati","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00333-24","DOI":"10.1128\/spectrum.00333-24","article-title":"Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia","volume":"12","author":"Yun","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections","volume":"45","author":"Kollef","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","first-page":"45","article-title":"Risk factors for therapeutic failure in adults with methicillin-resistant Staphylococcus aureus (MRSA) infection treated with vancomycin in a high-complexity hospital in Cali, Colombia","volume":"32","author":"Muriel","year":"2024","journal-title":"Infez. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ramos, S., Silva, V., Dapkevicius, M., Igrejas, G., and Poeta, P. (2020). Enterococci, from Harmless Bacteria to a Pathogen. Microorganisms, 8.","DOI":"10.20944\/preprints202007.0393.v1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Al Bshabshe, A., Algarni, A., Shabi, Y., Alwahhabi, A., Asiri, M., Alasmari, A., Alshehry, A., Mousa, W.F., and Noreldin, N. (2024). Characterization and Antimicrobial Susceptibility Patterns of Enterococcus Species Isolated from Nosocomial Infections in a Saudi Tertiary Care Hospital over a Ten-Year Period (2012\u20132021). Diagnostics, 14.","DOI":"10.3390\/diagnostics14111190"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13756-019-0594-3","article-title":"The rise in vancomycin-resistant Enterococcus faecium in Germany: Data from the German Antimicrobial Resistance Surveillance (ARS)","volume":"8","author":"Markwart","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_28","unstructured":"Bhardwaj, S.B. (2020). Enterococci: An Important Nosocomial Pathogen, IntechOpen."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.idc.2020.08.004","article-title":"Resistance in Vancomycin-Resistant Enterococci","volume":"34","author":"Miller","year":"2020","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4161\/viru.21282","article-title":"Intrinsic and acquired resistance mechanisms in Enterococcus","volume":"3","author":"Hollenbeck","year":"2012","journal-title":"Virulence"},{"key":"ref_31","unstructured":"(2026, March 31). Surveillance of Antimicrobial Resistance in Europe 2018. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41579-024-01116-z","article-title":"Streptococcus pneumoniae epidemiology, pathogenesis and control","volume":"23","author":"Narciso","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_33","unstructured":"(2026, March 31). 2019 Antibiotic Resistance Threats Report, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schroeder, M.R., and Stephens, D.S. (2016). Macrolide Resistance in Streptococcus pneumoniae. Front. Cell. Infect. Microbiol., 6.","DOI":"10.3389\/fcimb.2016.00098"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: Transmission, colonization and invasion","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.39.3.577","article-title":"Erythromycin resistance by ribosome modification","volume":"39","author":"Weisblum","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/fmb.12.63","article-title":"Acquired Inducible Antimicrobial Resistance in Gram-Positive Bacteria","volume":"7","author":"Chancey","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.45.1.1-12.2001","article-title":"Macrolide Resistance Conferred by Base Substitutions in 23S rRNA","volume":"45","author":"Vester","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"781679","DOI":"10.1155\/2012\/781679","article-title":"Glycopeptide Resistance in Gram-Positive Cocci: A Review","volume":"2012","author":"Sujatha","year":"2012","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00018-005-5148-6","article-title":"\u03b2-Lactam resistance in Staphylococcus aureus: The adaptive resistance of a plastic genome","volume":"62","author":"Fuda","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1128\/JCM.40.11.3970-3975.2002","article-title":"mecA Gene Is Widely Disseminated in Staphylococcus aureus Population","volume":"40","author":"Wielders","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","first-page":"76","article-title":"Distribution of genes encoding tetracycline resistance and aminoglycoside modifying enzymes in Staphylococcus aureus strains isolated from a burn center","volume":"26","author":"Emaneini","year":"2013","journal-title":"Ann. Burn Fire Disasters"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ajic.2006.05.219","article-title":"Mechanisms of antimicrobial resistance in bacteria","volume":"34","author":"Tenover","year":"2006","journal-title":"Am. J. Infect. Control"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mlynarczyk-Bonikowska, B., Kowalewski, C., Krolak-Ulinska, A., and Marusza, W. (2022). Molecular Mechanisms of Drug Resistance in Staphylococcus aureus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158088"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"fuaf057","DOI":"10.1093\/femsre\/fuaf057","article-title":"Resistance to last-resort antibiotics in enterococci","volume":"49","author":"Lu","year":"2025","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/AAC.35.6.1053","article-title":"Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis","volume":"35","author":"Nakanishi","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/JB.180.7.1831-1840.1998","article-title":"Acquisition of Five High-M rPenicillin-Binding Protein Variants during Transfer of High-Level \u03b2-Lactam Resistance from Streptococcus mitis to Streptococcus pneumoniae","volume":"180","author":"Hakenbeck","year":"1998","journal-title":"J. Bacteriol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1086\/340400","article-title":"Resistance among Streptococcus pneumoniae: Implications for Drug Selection","volume":"34","author":"Appelbaum","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/TCRM.S541780","article-title":"A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions","volume":"21","author":"Alharbi","year":"2025","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model","volume":"48","author":"Laplante","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter","volume":"57","author":"Paterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis","volume":"11","author":"Haikal","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dkaa184","article-title":"Relationship of vancomycin trough levels with acute kidney injury risk: An exposure\u2013toxicity meta-analysis","volume":"75","author":"Bellos","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M4-4","article-title":"Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (\u2018the MIC Creep\u2019): Implications for therapy","volume":"4","author":"Dhand","year":"2012","journal-title":"F1000 Med. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","article-title":"Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections\u2014A systematic review and meta-analysis","volume":"24","author":"Diaz","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.12669\/pjms.36.7.3273","article-title":"Assessment of Vancomycin MIC Creep Phenomenon in Methicillin-Resistant Staphylococcus aureus isolates in a Tertiary Care Hospital of Lahore","volume":"36","author":"Arshad","year":"2020","journal-title":"Pak. J. Med. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infe","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1073\/pnas.1613055113","article-title":"Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center","volume":"113","author":"Marks","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","first-page":"204993611982896","article-title":"Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia","volume":"6","author":"Narayanan","year":"2019","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1469-0691.2001.00061.x","article-title":"Linezolid: Pharmacokinetic characteristics and clinical studies","volume":"7","author":"Bouza","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhou, L., Yao, Q., Wang, Z., Yu, L., Yu, Z., and Zhao, Y. (2025). Comparative effectiveness and safety of vancomycin versus linezolid for the treatment of central nervous system infections: A meta-analysis. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1668983"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Peykov, S., Kirov, B., and Strateva, T. (2025). Linezolid in the Focus of Antimicrobial Resistance of Enterococcus Species: A Global Overview of Genomic Studies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178207"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41429-024-00778-4","article-title":"Resistance to linezolid in Staphylococcus aureus by mutation, modification, and acquisition of genes","volume":"78","author":"Yang","year":"2025","journal-title":"J. Antibiot."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsinfecdis.7b00251","article-title":"Antibiotic Resistance ABC-F Proteins: Bringing Target Protection into the Limelight","volume":"4","author":"Sharkey","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jac\/dky088","article-title":"Characterization of poxtA, a novel phenicol\u2013oxazolidinone\u2013tetracycline resistance gene from an MRSA of clinical origin","volume":"73","author":"Antonelli","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Dadashi, M., Sharifian, P., Bostanshirin, N., Hajikhani, B., Bostanghadiri, N., Khosravi-Dehaghi, N., Van Belkum, A., and Darban-Sarokhalil, D. (2021). The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains from Human Clinical Samples: A Systematic Review and Meta-Analysis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.720647"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/fmb-2023-0170","article-title":"Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: A systematic review and meta-analysis","volume":"19","author":"Heidary","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jgar.2020.03.027","article-title":"Molecular characteristics and risk factors associated with linezolid-resistant Enterococcus faecalis infection in Southwest China","volume":"22","author":"Zou","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.01308-10","article-title":"Emergence of Linezolid-Resistant Staphylococcus aureus after Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.bmc.2016.05.052","article-title":"The action mechanism of daptomycin","volume":"24","author":"Taylor","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/tcrm.2006.2.2.169","article-title":"A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections","volume":"2","author":"Shoemaker","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_79","first-page":"139","article-title":"Daptomycin use in adult inpatients in a Canadian tertiary care setting","volume":"4","author":"Tilak","year":"2019","journal-title":"J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12948","article-title":"Mechanisms of drug resistance: Daptomycin resistance","volume":"1354","author":"Tran","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16107","DOI":"10.1038\/s41598-020-73108-x","article-title":"Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA)","volume":"10","author":"Thitiananpakorn","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e01317-20","DOI":"10.1128\/AAC.01317-20","article-title":"Daptomycin Resistance in Enterococcus faecium Can Be Delayed by Disruption of the LiaFSR Stress Response Pathway","volume":"65","author":"Prater","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of Daptomycin, Tigecycline, Quinupristin\/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase\u2013negative staphylococci strains: A systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1099\/jmm.0.022533-0","article-title":"Six cases of daptomycin-non-susceptible Staphylococcus aureus bacteraemia in Singapore","volume":"59","author":"Hsu","year":"2010","journal-title":"J. Med. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1021\/ja8029448","article-title":"Co-opting the Cell Wall in Fighting Methicillin-Resistant Staphylococcus aureus: Potent Inhibition of PBP 2a by Two Anti-MRSA \u03b2-Lactam Antibiotics","volume":"130","author":"Lee","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of Streptococcus pneumoniae","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","unstructured":"(2026, April 05). Zinforo EPAR Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf."},{"key":"ref_90","unstructured":"(2026, April 05). Teflaro (Ceftaroline Fosamil), Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/200327s015lbl.pdf."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jmii.2020.04.017","article-title":"In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018","volume":"54","author":"Jean","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/AAC.03622-14","article-title":"PBP2a Mutations Causing High-Level Ceftaroline Resistance in Clinical Methicillin-Resistant Staphylococcus aureus Isolates","volume":"58","author":"Long","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Vittorakis, E., Vica, M.L., Zervaki, C.O., Vittorakis, E., Maraki, S., Mavromanolaki, V.E., Sch\u00fcrger, M.E., Neculicioiu, V.S., Papadomanolaki, E., and Junie, L.M. (2024). A Comparative Analysis of MRSA: Epidemiology and Antibiotic Resistance in Greece and Romania. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147535"},{"key":"ref_95","first-page":"143","article-title":"Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints","volume":"33","author":"Arun","year":"2023","journal-title":"Ethiop. J. Health Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e00586-25","DOI":"10.1128\/aac.00586-25","article-title":"Beyond mecA: A two-tiered mechanism and regulatory rewiring drive high-level ceftaroline resistance in clinical MRSA","volume":"70","author":"Sassman","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1179\/joc.2005.17.6.593","article-title":"Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol","volume":"17","author":"Jones","year":"2005","journal-title":"J. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: A Novel Once-Weekly Lipoglycopeptide Antibiotic","volume":"46","author":"Saravolatz","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: A novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1310\/hpj4909-851","article-title":"Dalbavancin","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"dlae163","DOI":"10.1093\/jacamr\/dlae163","article-title":"Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: Phenotypic and genomic characterization","volume":"6","author":"Barbier","year":"2024","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2018.11.011","article-title":"In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source","volume":"78","author":"Azrad","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hotz, J.F., Staudacher, M., Schefberger, K., Spettel, K., Schmid, K., Kriz, R., Schneider, L., Hagemann, J.B., Cyran, N., and Schmidt, K. (2024). Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09797-w"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/IDR.S69412","article-title":"Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections","volume":"8","author":"Stein","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: Mechanism of Action","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e01667-21","DOI":"10.1128\/AAC.01667-21","article-title":"Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010\u20132019)","volume":"66","author":"Carvalhaes","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s40121-025-01215-1","article-title":"A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?","volume":"14","author":"Hussein","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Tigecycline","volume":"4","author":"Wenzel","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2013.02.022","article-title":"Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004\u20132010","volume":"41","author":"Balode","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e00634-23","DOI":"10.1128\/spectrum.00634-23","article-title":"Tigecycline Resistance-Associated Mutations in the MepA Efflux Pump in Staphylococcus aureus","volume":"11","author":"Huang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.04174-14","article-title":"Genomic Analysis of Reduced Susceptibility to Tigecycline in Enterococcus faecium","volume":"59","author":"Cattoir","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"116088","DOI":"10.1016\/j.diagmicrobio.2023.116088","article-title":"Prevalence of tigecycline resistance in methicillin-resistant Staphylococcus aureus: A systematic review and meta-analysis","volume":"108","author":"Heidary","year":"2024","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nmni.2017.05.009","article-title":"Identification of tigecycline- and vancomycin-resistant Staphylococcus aureus strains among patients with urinary tract infection in Iran","volume":"19","author":"Yousefi","year":"2017","journal-title":"New Microbes New Infect."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12941-025-00806-7","article-title":"Genomic insights into the spread of vancomycin- and tigecycline-resistant Enterococcus faecium ST117","volume":"24","author":"Brajerova","year":"2025","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the Clinical Use of Vancomycin","volume":"60","author":"Molina","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","article-title":"Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.2147\/IDR.S395385","article-title":"Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients","volume":"15","author":"Maluangnon","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.burns.2021.08.016","article-title":"Continuous infusion versus intermittent infusion vancomycin in a burn center intensive care unit","volume":"47","author":"Schlobohm","year":"2021","journal-title":"Burns"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Adamu, Y., Puig-Asensio, M., Dabo, B., and Schweizer, M.L. (2024). Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0293423"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients with Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia with Vancomycin Minimum Inhibitory Concentration >1 mg\/L: A Matched Cohort Study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-Dose Daptomycin and Clinical Applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Parsons, J.B., Westgeest, A.C., Conlon, B.P., and Fowler, V.G. (2023). Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030455"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-019-03801-x","article-title":"Role of linezolid combination therapy for serious infections: Review of the current evidence","volume":"39","author":"Chen","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1128\/AAC.47.6.1902-1906.2003","article-title":"In Vitro Activities of Linezolid Combined with Other Antimicrobial Agents against Staphylococci, Enterococci, Pneumococci, and Selected Gram-Negative Organisms","volume":"47","author":"Sweeney","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.01501-05","article-title":"In Vitro and In Vivo Assessment of Linezolid Combined with Ertapenem: A Highly Synergistic Combination against Methicillin-Resistant Staphylococcus aureus","volume":"50","author":"Jacqueline","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage Treatment for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid with or Without Carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jgar.2026.03.005","article-title":"Clinical Outcomes of Linezolid Monotherapy versus Combination Therapy in Vancomycin-Resistant Enterococcal Infections","volume":"48","author":"Siriwattanakowit","year":"2026","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ajhp\/zxz101","article-title":"Treatment of tricuspid valve endocarditis with daptomycin and linezolid therapy","volume":"76","author":"Galanter","year":"2019","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jiac.2018.02.006","article-title":"A successful salvage therapy with daptomycin and linezolid for right-sided infective endocarditis and septic pulmonary embolism caused by methicillin-resistant Staphylococcus aureus","volume":"24","author":"Yazaki","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_140","first-page":"619321","article-title":"Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections","volume":"2011","author":"Nadrah","year":"2011","journal-title":"Chemother. Res. Pract."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.02192-12","article-title":"Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant \u03b2-Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Moderate Renal Impairment","volume":"57","author":"Moise","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter Cohort of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared with Other MRSA Treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jiph.2022.10.017","article-title":"The combination of daptomycin with \u03b2-lactam antibiotics is more effective than daptomycin alone for vancomycin-resistant Enterococcus faecium bloodstream infection","volume":"15","author":"Chuang","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40121-022-00754-1","article-title":"The Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study","volume":"12","author":"Tseng","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/mdr.2010.0001","article-title":"Daptomycin and Rifampin for the Treatment of Methicillin-Resistant Staphylococcus aureus Septic Pulmonary Emboli in the Absence of Endocarditis","volume":"16","author":"Gomez","year":"2010","journal-title":"Microb. Drug Resist."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1345\/aph.1M665","article-title":"Successful Treatment of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus Aureus Bacteremia with the Addition of Rifampin to Daptomycin","volume":"44","author":"Ahmad","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/jac\/dkx130","article-title":"Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs)","volume":"72","author":"Yim","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e01472-22","DOI":"10.1128\/aac.01472-22","article-title":"Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Em","volume":"67","author":"Mishra","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Petropoulou, C., Ioannou, P., Eleftherakis, G., Papazisi, S., Davoulos, C., Drosou, E., Spiliopoulou, A., Tsiata, E., Paliogianni, F., and Kofteridis, D. (2025). Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study. Pathogens, 14.","DOI":"10.3390\/pathogens14111109"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14787210.2022.2060820","article-title":"Role of dalbavancin as combination therapy: Evidence from the literature and clinical scenarios","volume":"20","author":"Cacopardo","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial Low-Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22590","article-title":"Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: The ARREST RCT","volume":"22","author":"Thwaites","year":"2018","journal-title":"Health Technol. Assess."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment Outcomes for Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J. Infect."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of Antistaphylococcal -Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1128\/AAC.04141-14","article-title":"Impact of the Combination of Daptomycin and Trimethoprim-Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant Staphylococcus aureus Infections","volume":"59","author":"Claeys","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clinthera.2016.12.005","article-title":"Combination Therapy with Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series","volume":"39","author":"Gritsenko","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/23744235.2018.1448110","article-title":"Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"50","author":"Oliver","year":"2018","journal-title":"Infect. Dis."},{"key":"ref_160","first-page":"204993611988650","article-title":"Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure","volume":"6","author":"Hornak","year":"2019","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"106735","DOI":"10.1016\/j.ijantimicag.2023.106735","article-title":"Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia","volume":"61","author":"Patel","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jiac.2023.10.024","article-title":"Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature","volume":"30","author":"Omori","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/87551225241227796","article-title":"A Retrospective Cohort Study Comparing Dual Therapy with Ceftaroline with Vancomycin or Daptomycin Monotherapy for High-Grade or Persistent MRSA Bacteremia","volume":"40","author":"Cabanilla","year":"2024","journal-title":"J. Pharm. Technol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"ofaf695.233","DOI":"10.1093\/ofid\/ofaf695.233","article-title":"P-2. Ceftaroline Monotherapy Versus Combination Therapy for Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: A Retrospective Cohort Study","volume":"13","author":"Althubyani","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1128\/AAC.45.11.3202-3204.2001","article-title":"Treatment of Vancomycin-Resistant Enterococcal Infections in the Immunocompromised Host: Quinupristin-Dalfopristin in Combination with Minocycline","volume":"45","author":"Raad","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41598-018-19986-8","article-title":"A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"S799","DOI":"10.1093\/ofid\/ofaa439.1791","article-title":"1611. Evaluating Clinical Outcomes and Efficacy of Daptomycin in Combination with a Beta-Lactam for the Treatment of Vancomycin-Resistant Enterococcus (VRE) Bacteremia","volume":"7","author":"Irusta","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/427806","article-title":"Risk Factors for Hematogenous Complications of Intravascular Catheter--Associated Staphylococcus aureus Bacteremia","volume":"40","author":"Fowler","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07853890.2013.878513","article-title":"Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: Clinical outcome and management","volume":"46","author":"Chaftari","year":"2014","journal-title":"Ann. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2023.02.042","article-title":"Low Utilization of Lead Extraction Among Patients with Infective Endocarditis and Implanted Cardiac Electronic Devices","volume":"81","author":"Sciria","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus Bacteremia","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/cid\/ciae234","article-title":"Rapid Diagnostic Tests and Antimicrobial Stewardship Programs for the Management of Bloodstream Infection: What Is Their Relative Contribution to Improving Clinical Outcomes? A Systematic Review and Network Meta-analysis","volume":"79","author":"Peri","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/cid\/civ447","article-title":"Randomized Trial of Rapid Multiplex Polymerase Chain Reaction\u2013Based Blood Culture Identification and Susceptibility Testing","volume":"61","author":"Banerjee","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmi.2019.07.007","article-title":"When not to start antibiotics: Avoiding antibiotic overuse in the intensive care unit","volume":"26","author":"Denny","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Geng, M., and Bai, L. (2020). Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles. Microorganisms, 8.","DOI":"10.3390\/microorganisms8081222"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Iaconis, A., De Plano, L.M., Caccamo, A., Franco, D., and Conoci, S. (2024). Anti-Biofilm Strategies: A Focused Review on Innovative Approaches. Microorganisms, 12.","DOI":"10.3390\/microorganisms12040639"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s43088-021-00141-8","article-title":"Phage therapy as a revolutionary medicine against Gram-positive bacterial infections","volume":"10","author":"Loganathan","year":"2021","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"128231","DOI":"10.1016\/j.micres.2025.128231","article-title":"Bacteriophage therapy for critical antibiotic-resistant Gram-positive bacteria: A systematic review of clinical researches","volume":"298","author":"Nie","year":"2025","journal-title":"Microbiol. Res."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Plumet, L., Ahmad-Mansour, N., Dunyach-Remy, C., Kissa, K., Sotto, A., Lavigne, J.-P., Costechareyre, D., and Molle, V. (2022). Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.907314"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jare.2025.08.001","article-title":"Emerging host-directed strategies for overcoming drug resistance and immune evasion in Staphylococcus aureus infections","volume":"83","author":"Zheng","year":"2026","journal-title":"J. Adv. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis","volume":"54","author":"Lodise","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drup.2018.10.002","article-title":"Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature","volume":"40","author":"Bender","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e02483-18","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14656566.2018.1512584","article-title":"Choosing the appropriate pharmacotherapy for multidrug-resistant Gram positive infections","volume":"19","author":"Fiore","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Tebano, G., Zaghi, I., Baldasso, F., Calgarini, C., Capozzi, R., Salvadori, C., Cricca, M., and Cristini, F. (2024). Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?. Pathogens, 13.","DOI":"10.3390\/pathogens13010088"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Carcione, D., Intra, J., Andriani, L., Campanile, F., Gona, F., Carletti, S., Mancini, N., Brigante, G., Cattaneo, D., and Baldelli, S. (2023). New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091304"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.glmedi.2024.100081","article-title":"Antimicrobial resistance: Impacts, challenges, and future prospects","volume":"2","author":"Ahmed","year":"2024","journal-title":"J. Med. Surg. Public Health"},{"key":"ref_190","unstructured":"(2026, April 10). Target Product Profiles for New Antibacterial Agents. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240121188\/."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/780\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:52:53Z","timestamp":1786611173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":190,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antibiotics15080780"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15080780","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}